
Last updated: 2026-09-15 21:09:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
GH Research PLC (GHRS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $27.66, with a market capitalisation of $1.87B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.04 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
$1.87B | |
$27.63 | |
$31.44 | |
$5.05 | |
$27.89 | |
111.92K | |
276.32K | |
-- | |
$31.44 | |
$12.04 | |
-- | |
-- |
GH Research PLC (GHRS) is trading at $28.53 in after-hours trading as of 2026-09-15 20:22:00, up 2.29% ($0.64) from the regular-session close of $27.89.
After-hours trading shows how investors are pricing GHRS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, GH Research PLC (GHRS) moved from $27.92 to $27.66, representing a decline of 0.93% ($0.26).
The stock traded between $25.82 and $28.62 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 171.23 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 80.5%
GHRS is currently trading at $27.66, placing it 80.5% of the way from its 52-week low of $12.04 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GH Research PLC (GHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.